Dr Alessandro Russo

All Stories

1. 
   Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

2. 
   Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

3. 
   Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

4. 
   Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

5. 
   Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

6. 
   Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

7. 
   Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

8. 
   Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

9. 
   Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

   Article • November 2025, American Association for Cancer Research (AACR)

   Dr Alessandro Russo

10. 
    Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

11. 
    Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

12. 
    Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

13. 
    Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

14. 
    Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

15. 
    Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

16. 
    Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

17. 
    Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

18. 
    Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

19. 
    Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

20. 
    Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

21. 
    Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy

    Article • Lung Cancer, September 2025, Elsevier

    Dr Alessandro Russo

22. 
    Could 18F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2− Patients?

    Article • Diagnostics, August 2025, MDPI AG

    Dr Alessandro Russo

23. 
    Game-Set-MATCH: Liquid Biopsy Advances to the Next Round

    Article • Clinical Cancer Research, August 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

24. 
    Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL

    Article • Lung Cancer, August 2025, Elsevier

    Dr Alessandro Russo

25. 
    Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer

    Article • JAMA Oncology, July 2025, American Medical Association (AMA)

    Dr Alessandro Russo

26. 
    Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study

    Article • Cancers, June 2025, MDPI AG

    Dr Alessandro Russo

27. 
    Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

    Article • Lung Cancer, June 2025, Elsevier

    Dr Alessandro Russo

28. 
    ADCs and TCE in SCLC Therapy: The Beginning of a New Era?

    Article • Current Oncology, April 2025, MDPI AG

    Dr Alessandro Russo

29. 
    Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group

    Article • Critical Reviews in Oncology/Hematology, April 2025, Elsevier

    Dr Alessandro Russo

30. 
    Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

    Article • Journal for ImmunoTherapy of Cancer, February 2025, BMJ

    Dr Alessandro Russo

31. 
    The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer

    Article • Discover Oncology, January 2025, Springer Science + Business Media

    Dr Alessandro Russo

32. 
    Advanced-Stage Alk-Positive Non–Small-Cell Lung Cancer (Nsclc) Patients: Real-World Treatment Patterns and Outcomes from the Italian Biomarker Atlas Database

    Article • January 2025, Elsevier

    Dr Alessandro Russo

33. 
    The relevance of the reference range for EGFR testing in non-small cell lung cancer patients

    Article • Lung Cancer, December 2024, Elsevier

    Dr Alessandro Russo

34. 
    Extracellular vesicles containing SARS‐CoV‐2 proteins are associated with multi‐organ dysfunction and worse outcomes in patients with severe COVID‐19

    Article • Journal of Extracellular Vesicles, November 2024, Wiley

    Dr Alessandro Russo

35. 
    Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting

    Article • Critical Reviews in Oncology/Hematology, October 2024, Elsevier

    Dr Alessandro Russo

36. 
    Facing an un-met need in lung cancer screening: The never smokers

    Article • Critical Reviews in Oncology/Hematology, October 2024, Elsevier

    Dr Alessandro Russo

37. 
    The Next Frontier for Colorectal Cancer Screening: Blood-Based Tests

    Article • Cancer Research, October 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

38. 
    Data from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

39. 
    Data from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

40. 
    Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

41. 
    Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

42. 
    Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

43. 
    Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

44. 
    Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

45. 
    Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

46. 
    Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

47. 
    Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

48. 
    Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

49. 
    Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

50. 
    Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

51. 
    Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

52. 
    Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

53. 
    Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

54. 
    Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

55. 
    Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

56. 
    Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

57. 
    Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

58. 
    Supplementary Table S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

59. 
    Supplementary Table S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

60. 
    Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

61. 
    Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

62. 
    Supplementary Table S11 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

63. 
    Supplementary Table S11 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

64. 
    Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

65. 
    Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

66. 
    Supplementary Table S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

67. 
    Supplementary Table S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

68. 
    Supplementary Table S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

69. 
    Supplementary Table S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

70. 
    Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

71. 
    Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

72. 
    Supplementary Table S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

73. 
    Supplementary Table S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

74. 
    Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

75. 
    Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

76. 
    Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

77. 
    Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

78. 
    Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

79. 
    Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

80. 
    Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

    Article • Clinical Lung Cancer, September 2024, Elsevier

    Dr Alessandro Russo

81. 
    The Chemoimmunotherapy Revolution in Resectable NSCLC—The Times They Are A-Changin’

    Article • JAMA Oncology, May 2024, American Medical Association (AMA)

    Dr Alessandro Russo

82. 
    Abstract 5134: Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

83. 
    Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC

    Article • Journal of Experimental & Clinical Cancer Research, March 2024, Springer Science + Business Media

    Dr Alessandro Russo

84. 
    Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)

    Article • Annals of Oncology, March 2024, Elsevier

    Dr Alessandro Russo

85. 
    Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens

    Article • The Journal of Liquid Biopsy, March 2024, Elsevier

    Dr Alessandro Russo

86. 
    Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer

    Article • Annals of Oncology, February 2024, Elsevier

    Dr Alessandro Russo

87. 
    Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment

    Article • JCO Precision Oncology, February 2024, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

88. 
    LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?

    Article • Med, February 2024, Elsevier

    Dr Alessandro Russo

89. 
    Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy

    Article • Frontiers in Immunology, January 2024, Frontiers

    Dr Alessandro Russo

90. 
    Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers

    Article • Cancer, January 2024, Wiley

    Dr Alessandro Russo

91. 
    Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

    Article • Lung Cancer, January 2024, Elsevier

    Dr Alessandro Russo

92. 
    Curvilinear Mesh Generation for the High-Order Virtual Element Method (VEM)

    Article • January 2024, Springer Science + Business Media

    Dr Alessandro Russo

93. 
    Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

    Article • European Journal of Cancer, January 2024, Elsevier

    Dr Alessandro Russo

94. 
    In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer

    Article • Clinical Cancer Research, December 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

95. 
    Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study

    Article • Translational Lung Cancer Research, December 2023, AME Publishing Company

    Dr Alessandro Russo

96. 
    Abstract B145: Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors

    Article • Molecular Cancer Therapeutics, December 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

97. 
    Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer

    Article • Biomarker Research, November 2023, Springer Science + Business Media

    Dr Alessandro Russo

98. 
    EP11.01-01 Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Alessandro Russo

99. 
    EP17.06-01 COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Alessandro Russo

100. 
     P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

     Article • Journal of Thoracic Oncology, November 2023, Elsevier

     Dr Alessandro Russo

101. 
     P1.22-19 Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions

     Article • Journal of Thoracic Oncology, November 2023, Elsevier

     Dr Alessandro Russo

102. 
     Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

     Article • Clinical Lung Cancer, November 2023, Elsevier

     Dr Alessandro Russo

103. 
     1403P Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program

     Article • Annals of Oncology, October 2023, Elsevier

     Dr Alessandro Russo

104. 
     2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy

     Article • Annals of Oncology, October 2023, Elsevier

     Dr Alessandro Russo

105. 
     2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC

     Article • Annals of Oncology, October 2023, Elsevier

     Dr Alessandro Russo

106. 
     New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group

     Article • Critical Reviews in Oncology/Hematology, October 2023, Elsevier

     Dr Alessandro Russo

107. 
     Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations

     Article • Clinical Cancer Research, September 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

108. 
     Brave new world of cfDNA-omics for early cancer detection

     Article • Journal for ImmunoTherapy of Cancer, September 2023, BMJ

     Dr Alessandro Russo

109. 
     Data from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

110. 
     Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

111. 
     Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

112. 
     Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

113. 
     Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

114. 
     Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

115. 
     Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

116. 
     Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

117. 
     Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

118. 
     Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

119. 
     Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

120. 
     Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

121. 
     Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

122. 
     Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

123. 
     Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

124. 
     Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

125. 
     Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

126. 
     Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

127. 
     Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

128. 
     Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

129. 
     Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

130. 
     Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

131. 
     Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

132. 
     Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

133. 
     Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

134. 
     Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

135. 
     Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

136. 
     Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

137. 
     Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

138. 
     Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

139. 
     Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

140. 
     Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

141. 
     Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

142. 
     Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

143. 
     Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

144. 
     Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

145. 
     Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

146. 
     Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

147. 
     Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

148. 
     Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

149. 
     Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • July 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

150. 
     Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study

     Article • La radiologia medica, June 2023, Springer Science + Business Media

     Dr Alessandro Russo

151. 
     Data from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

152. 
     Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

153. 
     Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

154. 
     Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

155. 
     Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

156. 
     Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

157. 
     Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

158. 
     Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

159. 
     Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

160. 
     Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

161. 
     Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

162. 
     Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

163. 
     Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

164. 
     Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

165. 
     Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

166. 
     Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

167. 
     Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

168. 
     Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

169. 
     Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

170. 
     Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

171. 
     Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

172. 
     Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

173. 
     Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

174. 
     Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

175. 
     Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

176. 
     Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

177. 
     Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

178. 
     Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

179. 
     Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

180. 
     Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

181. 
     Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

182. 
     Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

183. 
     Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

184. 
     Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

185. 
     Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

186. 
     Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

187. 
     Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

188. 
     Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

189. 
     Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

190. 
     Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

191. 
     Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

192. 
     Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction–Based Testing

     Article • Journal of Thoracic Oncology, June 2023, Elsevier

     Dr Alessandro Russo

193. 
     Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

     Article • Clinical Cancer Research, June 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

194. 
     The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution?

     Article • EBioMedicine, June 2023, Elsevier

     Dr Alessandro Russo

195. 
     RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

     Article • Journal of Thoracic Oncology, May 2023, Elsevier

     Dr Alessandro Russo

196. 
     Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study

     Article • Targeted Oncology, April 2023, Springer Science + Business Media

     Dr Alessandro Russo

197. 
     Abstract 4329: Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy

     Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

198. 
     Moving Forward Liquid Biopsy in Early Liver Cancer Detection

     Article • Cancer Discovery, March 2023, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

199. 
     Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non–Small-Cell Lung Cancer

     Article • JCO Precision Oncology, February 2023, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

200. 
     Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis

     Article • Frontiers in Endocrinology, January 2023, Frontiers

     Dr Alessandro Russo

201. 
     B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?

     Article • International Journal of Molecular Sciences, December 2022, MDPI AG

     Dr Alessandro Russo

202. 
     Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer

     Article • Cancer, December 2022, Wiley

     Dr Alessandro Russo

203. 
     A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA

     Article • Translational Lung Cancer Research, October 2022, AME Publishing Company

     Dr Alessandro Russo

204. 
     Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions

     Article • European Journal of Cancer, October 2022, Elsevier

     Dr Alessandro Russo

205. 
     The evolving landscape of anatomic pathology

     Article • Critical Reviews in Oncology/Hematology, October 2022, Elsevier

     Dr Alessandro Russo

206. 
     The evolving role of liquid biopsy in lung cancer

     Article • Lung Cancer, October 2022, Elsevier

     Dr Alessandro Russo

207. 
     1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC

     Article • Annals of Oncology, September 2022, Elsevier

     Dr Alessandro Russo

208. 
     996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)

     Article • Annals of Oncology, September 2022, Elsevier

     Dr Alessandro Russo

209. 
     Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)

     Article • Clinical Lung Cancer, September 2022, Elsevier

     Dr Alessandro Russo

210. 
     Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients

     Article • Cancer Research, August 2022, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

211. 
     Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors

     Article • ESMO Open, August 2022, Elsevier

     Dr Alessandro Russo

212. 
     STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

     Article • Lung Cancer, August 2022, Elsevier

     Dr Alessandro Russo

213. 
     Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives

     Article • Cancers, July 2022, MDPI AG

     Dr Alessandro Russo

214. 
     Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question

     Article • Pharmaceutics, June 2022, MDPI AG

     Dr Alessandro Russo

215. 
     Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

     Article • Journal of Experimental & Clinical Cancer Research, June 2022, Springer Science + Business Media

     Dr Alessandro Russo

216. 
     Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era

     Article • Critical Reviews in Oncology/Hematology, June 2022, Elsevier

     Dr Alessandro Russo

217. 
     Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

     Article • ESMO Open, April 2022, Elsevier

     Dr Alessandro Russo

218. 
     Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’

     Article • ESMO Open, April 2022, Elsevier

     Dr Alessandro Russo

219. 
     Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

     Article • Journal of Thoracic Oncology, February 2022, Elsevier

     Dr Alessandro Russo

220. 
     High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

     Article • Journal of Hematology & Oncology, January 2022, Springer Science + Business Media

     Dr Sebastiano Buti, Dr Alessandro Russo

221. 
     Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy

     Article • Therapeutic Advances in Medical Oncology, January 2022, SAGE Publications

     Dr Alessandro Russo

222. 
     KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

     Article • Therapeutic Advances in Respiratory Disease, January 2022, SAGE Publications

     Dr Alessandro Russo

223. 
     p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics

     Article • Translational Oncology, January 2022, Elsevier

     Dr Alessandro Russo

224. 
     Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

     Article • Theranostics, January 2022, Ivyspring International Publisher

     Dr Alessandro Russo

225. 
     A New Generation of Vaccines in the Age of Immunotherapy

     Article • Current Oncology Reports, November 2021, Springer Science + Business Media

     Dr Alessandro Russo

226. 
     23 Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients

     Article • November 2021, BMJ

     Dr Alessandro Russo

227. 
     Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

     Article • Expert Review of Molecular Diagnostics, October 2021, Taylor & Francis

     Dr Alessandro Russo

228. 
     Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer

     Article • Cancers, October 2021, MDPI AG

     Dr Alessandro Russo

229. 
     Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

     Article • Nature Reviews Clinical Oncology, October 2021, Springer Science + Business Media

     Dr Alessandro Russo

230. 
     Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?

     Article • Expert Review of Anticancer Therapy, September 2021, Taylor & Francis

     Dr Alessandro Russo

231. 
     EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

     Article • Nature Reviews Clinical Oncology, September 2021, Springer Science + Business Media

     Dr Alessandro Russo

232. 
     NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

     Article • British Journal of Cancer, September 2021, Springer Science + Business Media

     Dr Alessandro Russo

233. 
     966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy

     Article • Annals of Oncology, September 2021, Elsevier

     Dr Alessandro Russo

234. 
     Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib

     Article • Precision Cancer Medicine, September 2021, AME Publishing Company

     Dr Alessandro Russo

235. 
     Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

     Article • Medical Oncology, August 2021, Springer Science + Business Media

     Dr Sebastiano Buti, Dr Alessandro Russo

236. 
     Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy

     Article • Translational Lung Cancer Research, July 2021, AME Publishing Company

     Dr Alessandro Russo

237. 
     Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review

     Article • Translational Lung Cancer Research, July 2021, AME Publishing Company

     Dr Alessandro Russo

238. 
     PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

     Article • Journal of Translational Medicine, June 2021, Springer Science + Business Media

     Dr Sebastiano Buti, Dr Alessandro Russo

239. 
     Platelets Lead Morphological, Phenotypic and Functional Changes in Tumor Cells.

     Article • June 2021, Springer Science + Business Media

     Dr Alessandro Russo

240. 
     Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

     Article • European Journal of Cancer, June 2021, Elsevier

     Dr Sebastiano Buti, Dr Alessandro Russo

241. 
     Dynamic levels of extracellular vesicle PD-L1 and complementary radiomics for the prediction of the response to immune checkpoint inhibitors in lung cancer patients.

     Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

242. 
     Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

     Article • European Journal of Cancer, May 2021, Elsevier

     Dr Sebastiano Buti, Dr Alessandro Russo

243. 
     Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021

     Article • Critical Reviews in Oncology/Hematology, May 2021, Elsevier

     Dr Alessandro Russo

244. 
     Abstract PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients

     Article • Clinical Cancer Research, April 2021, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

245. 
     Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective

     Article • Cancers, April 2021, MDPI AG

     Dr Alessandro Russo

246. 
     117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients

     Article • Journal of Thoracic Oncology, April 2021, Elsevier

     Dr Alessandro Russo

247. 
     Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

     Article • Journal for ImmunoTherapy of Cancer, April 2021, BMJ

     Dr Alessandro Russo

248. 
     When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review

     Article • Oncology and Therapy, March 2021, Springer Science + Business Media

     Dr Alessandro Russo

249. 
     Radiomic Detection of EGFR Mutations in NSCLC

     Article • Cancer Research, February 2021, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

250. 
     Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

     Article • European Journal of Cancer, January 2021, Elsevier

     Dr Sebastiano Buti, Dr Alessandro Russo

251. 
     Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

     Article • January 2021, Springer Science + Business Media

     Dr Alessandro Russo

252. 
     Treatment Toxicity

     Article • January 2021, Springer Science + Business Media

     Dr Alessandro Russo

253. 
     BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

     Article • Critical Reviews in Oncology/Hematology, December 2020, Elsevier

     Dr Alessandro Russo

254. 
     Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies

     Article • Translational Lung Cancer Research, December 2020, AME Publishing Company

     Dr Alessandro Russo

255. 
     Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

     Article • Journal for ImmunoTherapy of Cancer, November 2020, BMJ

     Dr Alessandro Russo

256. 
     Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

     Article • Cancer Discovery, November 2020, American Association for Cancer Research (AACR)

     Dr Alessandro Russo, Dr Juan J Diaz-Mochon

257. 
     Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer

     Article • Journal of Thoracic Oncology, November 2020, Elsevier

     Dr Alessandro Russo

258. 
     Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America

     Article • JCO Global Oncology, November 2020, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

259. 
     31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients

     Article • November 2020, BMJ

     Dr Alessandro Russo

260. 
     Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]

     Article • Critical Reviews in Oncology/Hematology, October 2020, Elsevier

     Dr Alessandro Russo, Dr Juan J Diaz-Mochon

261. 
     Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report

     Article • Translational Lung Cancer Research, October 2020, AME Publishing Company

     Dr Alessandro Russo

262. 
     Targeted Therapies in Early Stage NSCLC: Hype or Hope?

     Article • International Journal of Molecular Sciences, August 2020, MDPI AG

     Dr Alessandro Russo

263. 
     Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

     Article • European Journal of Cancer, July 2020, Elsevier

     Dr Alessandro Russo

264. 
     Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

     Article • Critical Reviews in Oncology/Hematology, July 2020, Elsevier

     Dr Alessandro Russo, Dr Juan J Diaz-Mochon

265. 
     NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC)

     Article • Precision Cancer Medicine, June 2020, AME Publishing Company

     Dr Alessandro Russo

266. 
     Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy

     Article • Cancer, May 2020, Wiley

     Dr Alessandro Russo

267. 
     Liquid biopsy for early stage lung cancer moves ever closer

     Article • Nature Reviews Clinical Oncology, May 2020, Springer Science + Business Media

     Dr Alessandro Russo

268. 
     HER2 Mutations in Non–Small Cell Lung Cancer: A Herculean Effort to Hit the Target

     Article • Cancer Discovery, May 2020, American Association for Cancer Research (AACR)

     Dr Alessandro Russo

269. 
     Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

     Article • Cancers, April 2020, MDPI AG

     Dr Alessandro Russo

270. 
     New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

     Article • Current Oncology Reports, April 2020, Springer Science + Business Media

     Dr Alessandro Russo

271. 
     Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study

     Article • April 2020, Cold Spring Harbor Laboratory Press

     Dr Alessandro Russo

272. 
     A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection

     Article • Cancers, March 2020, MDPI AG

     Dr Alessandro Russo

273. 
     Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

     Article • Expert Opinion on Biological Therapy, February 2020, Taylor & Francis

     Dr Alessandro Russo

274. 
     Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

     Article • Advances in Therapy, January 2020, Springer Science + Business Media

     Dr Alessandro Russo

275. 
     Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

     Article • Cancers, January 2020, MDPI AG

     Dr Alessandro Russo

276. 
     Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten

     Article • Kompass Pneumologie, January 2020, Karger Publishers

     Dr Alessandro Russo

277. 
     Understanding EGFR heterogeneity in lung cancer

     Article • ESMO Open, January 2020, Elsevier

     Dr Alessandro Russo

278. 
     Immunotherapy in Lung Cancer: From a Minor God to the Olympus

     Article • January 2020, Springer Science + Business Media

     Dr Alessandro Russo

279. 
     RET fusions in solid tumors

     Article • Cancer Treatment Reviews, December 2019, Elsevier

     Dr Alessandro Russo

280. 
     55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

     Article • Annals of Oncology, December 2019, Oxford University Press (OUP)

     Dr Alessandro Russo

281. 
     Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

     Article • Translational Cancer Research, December 2019, AME Publishing Company

     Dr Alessandro Russo

282. 
     Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma

     Article • Cancers, November 2019, MDPI AG

     Dr Alessandro Russo

283. 
     O.01 Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are ESCAT and OncoKB Scales Reliable?

     Article • Journal of Thoracic Oncology, November 2019, Elsevier

     Dr Alessandro Russo

284. 
     Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC

     Article • JCO Precision Oncology, November 2019, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

285. 
     Liquid biopsy tracking of lung tumor evolutions over time

     Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

     Dr Alessandro Russo, Professor VINCENZO ADAMO, francesco pepe

286. 
     Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

     Article • Critical Reviews in Oncology/Hematology, October 2019, Elsevier

     Dr Alessandro Russo

287. 
     1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?

     Article • Annals of Oncology, October 2019, Oxford University Press (OUP)

     Dr Alessandro Russo

288. 
     P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy

     Article • Journal of Thoracic Oncology, October 2019, Elsevier

     Dr Alessandro Russo

289. 
     Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study

     Article • Cancers, July 2019, MDPI AG

     Dr Alessandro Russo

290. 
     How I treat ALK-positive non-small cell lung cancer

     Article • ESMO Open, July 2019, BMJ

     Dr Alessandro Russo

291. 
     Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).

     Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

292. 
     Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

     Article • International Journal of Molecular Sciences, March 2019, MDPI AG

     Dr Alessandro Russo

293. 
     Immunotherapy use in patients with hiv and non-small-cell lung cancer: Current data

     Article • Journal of Immunotherapy and Precision Oncology, January 2019, Medknow

     Dr Alessandro Russo

294. 
     The changing scenario of 1 st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

     Article • Critical Reviews in Oncology/Hematology, October 2018, Elsevier

     Dr Alessandro Russo

295. 
     P1.04-28 Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study

     Article • Journal of Thoracic Oncology, October 2018, Elsevier

     Dr Alessandro Russo

296. 
     Acquired resistance in oncogene-addicted non-small-cell lung cancer

     Article • Future Oncology, June 2018, Future Medicine

     Dr Alessandro Russo

297. 
     Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

     Article • Journal of Cellular Physiology, April 2018, Wiley

     Professor VINCENZO ADAMO, Dr Alessandro Russo

298. 
     Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

     Article • BMC Cancer, January 2018, Springer Science + Business Media

     Dr Alessandro Russo

299. 
     E22Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

     Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

     Dr Alessandro Russo

300. 
     N2Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung

     Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

     Dr Alessandro Russo

301. 
     Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

     Article • Critical Reviews in Oncology/Hematology, September 2017, Elsevier

     Dr Alessandro Russo

302. 
     Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis.

     Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

303. 
     Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer

     Article • Expert Opinion on Pharmacotherapy, May 2017, Taylor & Francis

     Dr Alessandro Russo, Professor VINCENZO ADAMO

304. 
     Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

     Article • Oncotarget, January 2017, Impact Journals, LLC

     Dr Alessandro Russo

305. 
     Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation

     Article • Journal of Thoracic Oncology, January 2017, Elsevier

     Dr Alessandro Russo

306. 
     P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study

     Article • Journal of Thoracic Oncology, January 2017, Elsevier

     Dr Alessandro Russo

307. 
     Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

     Article • Cancer Biology & Therapy, August 2016, Taylor & Francis

     Dr Alessandro Russo

308. 
     Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

     Article • OncoTargets and Therapy, July 2016, Dove Medical Press

     Professor VINCENZO ADAMO, Dr Alessandro Russo

309. 
     The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

     Article • Oncotarget, June 2016, Impact Journals, LLC

     MICHELE DE TURSI, Dr Alessandro Russo

310. 
     Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes.

     Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

311. 
     Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

     Article • Expert Review of Anticancer Therapy, May 2016, Taylor & Francis

     Dr Alessandro Russo

312. 
     H44Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung

     Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

     Dr Alessandro Russo

313. 
     H47The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis

     Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

     Dr Alessandro Russo

314. 
     A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

     Article • Oncotarget, June 2015, Impact Journals, LLC

     Dr Alessandro Russo

315. 
     The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.

     Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

316. 
     147P * DIFFERENT METASTATIC PATTERN ACCORDING TO THE EGFR MUTATIONAL STATUS IN A COHORT OF LUNG ADENOCARCINOMAS (ADCs): A SINGLE-INSTITUTION REPORT

     Article • Annals of Oncology, April 2015, Oxford University Press (OUP)

     Dr Alessandro Russo

317. 
     159P * IMPACT OF MAINTENANCE PEMETREXED IN THE MANAGEMENT OF NON-PROGRESSING MALIGNANT MESOTHELIOMAS AFTER STANDARD FIST-LINE CHEMOTHERAPY: A SINGLE INSTITUTION EXPERIENCE

     Article • Annals of Oncology, April 2015, Oxford University Press (OUP)

     Dr Alessandro Russo

318. 
     Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

     Article • OncoTargets and Therapy, February 2015, Taylor & Francis

     Professor VINCENZO ADAMO, Dr Alessandro Russo

319. 
     NSCLC and HER2: Between Lights and Shadows

     Article • Journal of Thoracic Oncology, December 2014, Elsevier

     Dr Alessandro Russo

320. 
     Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EGFR-mutated and wild-type (WT) non-small cell lung cancer (NSCLC): A survival analysis.

     Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

     Dr Alessandro Russo

321. 
     47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?

     Article • Lung Cancer, May 2013, Elsevier

     Dr Alessandro Russo